Simon D

[Simon D @SimonDesrosier2]

@HOThomasWPhelps Still expected at ASH in December? They’ve been very quiet about ALPS lately

[Simon D @SimonDesrosier2]

@avidresearch Nice call! Thanks!

[Simon D @SimonDesrosier2]

@cashmeowsai @LucasCrabapple @A_May_MD We just need to hold tight, xmas will be wonderful

[Simon D @SimonDesrosier2]

@mgrm002 I doubt he sold anything, $CRVS just proved its MOA, the best is to come

[Simon D @SimonDesrosier2]

@HOThomasWPhelps Sad to hear that! Hope we’ll keep in touch! Thanks again for all your sharings. Take care!

[Simon D @SimonDesrosier2]

@lcccc333 Four cohorts with similar responses, dosing correlations, matching MOA expectations. Can't be coincidence…

[Simon D @SimonDesrosier2]

Good question for Grok

Dr Miller mentioned on biotech tv that ALPS trial will be extended to pts under 16. What would that mean regarding the safety and efficiency of soquelitinib and what should we expect as coming news and $CRVS price reaction.

ALPS update anytime soon

[Simon D @SimonDesrosier2]

@HOThomasWPhelps The kind of video I can easily show to friends and they understand. Thanks again

[Simon D @SimonDesrosier2]

About ten years ago, $CRVS raised $1 billion with just a few molecule ideas on paper. Imagine what they could raise today, with a validated SQL proof of concept and an advanced FDA approval process and large TAM

[Simon D @SimonDesrosier2]

@pmill145 @lcccc333 Cantor

[Simon D @SimonDesrosier2]

@HOThomasWPhelps I owe you and Corvus owe you! Can’t imagine the stock price and the company position today without your posts!

[Simon D @SimonDesrosier2]

@septdecoeur @wz2013 A BOMB

[Simon D @SimonDesrosier2]

@agamemnus_dev @wz2013 @septdecoeur Im pretty sure there is already a lineup of interested partners. Dupi-like oral and safe and we can easily have a good deal. My opinion, glad to be on the train

[Simon D @SimonDesrosier2]

@wz2013 @septdecoeur A low number could still be a homerun but badly interpreted $crvs

[Simon D @SimonDesrosier2]

@wz2013 @septdecoeur Again, it depends on patients baseline, prior tx failures, harder to treat, etc. Hopefully Dr Miller will be able to detail all that precisely.

[Simon D @SimonDesrosier2]

$CRVS It will be important to focus on the details concerning the patients in cohort 4, probably composed of patients who are more difficult to treat, failed jak and dupi, etc. Good luck!!

[Simon D @SimonDesrosier2]

Im pretty sure every ones present at jpm have access to internet to catch up on $crvs call

[Simon D @SimonDesrosier2]

If you're worrying that the $CRVS stock price will behave like it did in December 2024, I recommend you look at these charts instead. I don't believe in coincidences here and predict a wider separation from the placebo at 8 weeks of treatment.

[Simon D @SimonDesrosier2]

@mgrm002 @RybeccaSmith33 I can see it too, I hope you’re wrong 🙂